Top Qs
Timeline
Chat
Perspective
Denintuzumab mafodotin
Pharmaceutical drug From Wikipedia, the free encyclopedia
Remove ads
Denintuzumab mafodotin (INN; development codes SGN-19A or SGN-CD19A) is a humanized monoclonal antibody-drug conjugate designed for the treatment of CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.[1][2][3][4] It consists of an anti-CD19 mAb linked to monomethyl auristatin F (MMAF), a cytotoxic agent.[5] This drug was developed by Seattle Genetics.
Denintuzumab refers to the anti-CD19 antibody, and mafodotin refers to MMAF and the chemical linkage.[6]
Remove ads
Clinical trials
The drug is in phase I clinical trials.[7] Preliminary phase I results for B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) and B-lineage acute lymphocytic leukemia (B-ALL) were presented at the ASH medical conference Dec 2015.[4]
Phase 2
A separate randomized phase 2 trial started in 2015 to evaluate SGN-CD19A in combination with R-ICE chemotherapy for second-line DLBCL.[4] A phase 2 clinical trial in front-line DLBCL is started in 2016.[4] Both trials were terminated by the sponsor based on portfolio prioritization.[8][9]
Remove ads
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads